Clinical Trial Alert

Nephrology Times:
doi: 10.1097/01.NEP.0000418525.23998.03
Clinical Trial Alert

    The following is a partial list of new clinical trials recently added to the National Institutes of Health's ClinicalTrials.gov online registry. More information on these trials is available at www.clinicaltrials.gov.

    Back to Top | Article Outline

    • Acute Kidney Injury •

    NCT01621152

    Prevention of Acute Kidney Injury Initiated with Electronic Surveillance Enhancement (PRAISE)

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Mayo Clinic

    Contact: Kianoush Kashani, MD

    Phone: 507-266-7093

    E-mail: kashani.kianoush@mayo.edu

    Contact: Abbasali Akhoundi, MD

    Phone: 507-266-7093

    E-mail: akhoundi.abbasali@mayo.edu

    Back to Top | Article Outline
    NCT01602328

    A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects (ACT-AKI)

    Ages eligible for study: 21 years and older

    Sponsors and collaborators: AlloCure

    Contact: Elizabeth A. LaPointe, MA

    Phone: 978-400-8126

    E-mail: elapointe@allocure.com

    Contact: Viken Paragamian

    Phone: 416-427-1475

    E-mail: vikp@allocure.com

    Back to Top | Article Outline
    NCT01594489

    Aminophylline and Contrast-Induced Nephropathy in Acute Myocardial Infarction

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Ospedale Misericordia e Dolce (Misericordia and Dolce Hospital)

    Contact: Mauro Maioli, MD

    Phone: +39 0574 434396

    E-mail: mauro.maioli@fastwebnet.it

    Back to Top | Article Outline
    NCT01625403

    Recombinant BNP on Heart and Renal Function in Acute Heart Failure

    Ages eligible for study: 18 years to 80 years

    Sponsors and collaborators: Shanghai Chest Hospital

    Contact: Fang Yuan

    E-mail: yuanfangysh@126.com

    Back to Top | Article Outline

    • Anemia •

    NCT01599507

    Study of FG-4592 in Subjects with Chronic Kidney Disease in China

    Ages eligible for study: 18 years to 75 years

    Sponsors and collaborators: FibroGen

    Contact: Dalvin Ni, MD, PhD

    Phone: 86-13901772047

    E-mail: dni@fibrogen.com

    Contact: Frank Valone, MD

    Phone: 415-978-1520

    E-mail: fvalone@fibrogen.com

    Back to Top | Article Outline

    • Diabetes •

    NCT01617824

    Rapid Effects of Linagliptin on Monocyte Polarization in Type 2 Diabetes

    Ages eligible for study: 35 years to 75 years

    Sponsors and collaborators: University of Padova

    Contact: Angelo Avogaro, MD, PhD

    Phone: +39 049 8212178

    E-mail: angelo.avogaro@unipd.it

    Contact: Gian Paolo Fadini, MD

    Phone: +39 049 8214318

    E-mail: gianpaolo.fadini@unipd.it

    Back to Top | Article Outline
    NCT01601236

    Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Questcor Pharmaceuticals

    Contact: Jay Elliott

    Phone: 513-579-9911, ext. 2032

    E-mail: j.elliott@medpace.com

    Contact: Mary Nyberg

    Phone: 443-973-2015

    E-mail: mary.nyberg@questcor.com

    Back to Top | Article Outline

    • Hemodialysis •

    NCT01612429

    Carbamylation in Renal Disease Modulation with Amino Acid Therapy (CarRAAT)

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Massachusetts General Hospital

    Contact: Sahir Kalim, MD

    Phone: 617-726-5050

    E-mail: skalim@partners.org

    Contact: Dorothy Sullivan, RN

    Phone: 617-726-5382

    E-mail: dsullivan18@partners.org

    Back to Top | Article Outline

    • Hypertension •

    NCT01617551

    Effect of Renal Denervation on NO-Mediated Sodium Excretion and Plasma Levels of Vasoactive Hormones (RENO)

    Ages eligible for study: 30 years to 70 years

    Sponsors and collaborators: Regional Hospital Holstebro, Aarhus University Hospital

    Contact: Jesper N. Bech, MD, PhD

    Phone: +45 41627639

    E-mail: jnbech@dadlnet.dk

    Back to Top | Article Outline
    NCT01609959

    New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood-Pressure Lowering (NARA)

    Sponsors and collaborators: Nara Medical University

    Contact: Yoshihiko Saito, MD, PhD

    Phone: +81-744-22-3051, ext. 3411

    E-mail: yssaito@naramed-u.ac.jp

    Contact: Sadanori Okada, MD, PhD

    Phone: +81-744-22-3051, ext. 3411

    E-mail: saokada@naramed-u.ac.jp

    Back to Top | Article Outline

    • Transplantation •

    NCT01609673

    Study of Everolimus in De Novo Renal Transplant Recipients

    Ages eligible for study: 18 years to 85 years

    Sponsors and collaborators: Novartis Biociências SA (Novartis Biosciences SA)

    Contact: Hélady S. Pinheiro, MD, PhD

    Phone: +55 (32) 9982 8439

    E-mail: heladysanders@gmail.com

    Contact: Maria S. van Keulen, RN

    Phone: +55 (32) 8437 6754

    E-mail: maria.keulen@hotmail.com

    Back to Top | Article Outline
    NCT01615341

    Study of Subclinical Viral Infection

    Ages eligible for study: 1 year to 25 years

    Sponsors and collaborators: Seattle Children's Hospital, University of Washington

    Contact: Jodi Smith, MD

    Phone: 206-987-2524

    E-mail: jodi.smith@seattlechildrens.org

    Contact: Shannon Granillo

    Phone: 206-884-1418

    E-mail: shannon.granillo@seattlechildrens.org

    Back to Top | Article Outline
    NCT01615900

    Randomized Open-Label Study Evaluating the Coverage by Teleconsultation Versus Standard Follow-Up of Renal Transplant Patients According to a Risk Score of Early Graft Failure (KTFS) (TELEGRAFT)

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Nantes University Hospital

    Contact: Aurélie Meurette

    Phone: +33 2 40 08 74 35

    E-mail: aurelie.meurette@chu-nantes.fr

    Back to Top | Article Outline
    NCT01622881

    Analgesic Efficacy of Nefopam in Patients Undergoing Kidney Transplantation

    Ages eligible for study: 20 years to 59 years

    Sponsors and collaborators: Severance Hospital

    Contact: Yong Seon Choi, MD, PhD

    Phone: 82-2-2227-4576

    E-mail: yschoi@yuhs.ac

    Contact: So Yeon Kim, MD, PhD

    Phone: 82-2-2227-4470

    E-mail: kimsy326@yuhs.ac

    Back to Top | Article Outline
    NCT01608412

    A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus

    Ages eligible for study: 18 years and older Sponsors and collaborators: Hospital de Clinicas de Porto Alegre (Clinical Hospital of Porto Alegre)

    Contact: Luiz Felipe S. Gonçalves, MD

    E-mail: lfgoncalves@hcpa.ufrgs.br

    Contact: Nisséia Jahn, RN

    E-mail: nisseia@yahoo.com.br

    Back to Top | Article Outline
    NCT01612299

    Effects of Zortress plus Tacrolimus Versus Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in De Novo Renal Transplant Recipients

    Sponsors and collaborators: University of Kentucky

    Contact: Hartmut Malluche, MD

    Phone: 859-323-5049

    E-mail: hhmall@uky.edu

    Contact: Roberto Gedaly, MD

    Phone: 859-323-4661

    E-mail: rgeda2@uky.edu

    Back to Top | Article Outline
    NCT01602861

    The Effects of Spironolactone on Calcineurin Inhibitor-Induced Nephrotoxicity (SPIREN)

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Odense University Hospital, Fredericia Hospital

    Contact: Line A. Mortensen, MD

    Phone: 0045 30299610

    E-mail: line_maas@hotmail.com

    Back to Top | Article Outline
    NCT01614665

    A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Antirejection Medication Tacrolimus (Advagraf or Prograf) in Children Receiving an Organ Transplant, and How Safe and Effective They Are over a Longer Period of Time

    Ages eligible for study: up to 15 years

    Sponsors and collaborators: Astellas Pharma Europe

    Contact: Medical Affairs Europe

    Phone: +44 1784 419400

    E-mail: contact@nl.astellas.com

    Back to Top | Article Outline

    • Vascular Access •

    NCT01604473

    Endothelial Function and Arteriovenous Fistula Maturation

    Ages eligible for study: 18 years to 90 years

    Sponsors and collaborators: University of California, San Francisco

    Contact: Hugh F. Alley

    Phone: 415-221-4810, ext. 4708

    E-mail: hugh.alley@ucsfmedctr.org

    Contact: Christine Hall

    Phone: 415-221-4810, ext. 2115

    E-mail: christine.hall@ucsfmedctr.org

    Back to Top | Article Outline
    NCT01597115

    Enhancing Maturation of Autogenous Arteriovenous Hemodialysis Access by Aggressive Surveillance with Duplex and Endovascular Treatment (ENHANCE)

    Ages eligible for study: 20 years to 70 years

    Sponsors and collaborators: Seoul National University Hospital

    Contact: Sang-Il Min

    Phone: 82-2-2072-2330

    E-mail: surgeonmsi@gmail.com

    Back to Top | Article Outline
    NCT01601873

    Propaten Randomized Investigation on Cost–Benefit and Efficacy (PRICE)

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: University of Texas Health Science Center at Houston

    Contact: Kristofer M. Charlton-Ouw, MD

    Phone: 713-486-5100

    E-mail: kristofer.charltonouw@uth.tmc.edu

    Contact: Harleen K. Sandhu, MD

    Phone: 713-486-5100

    E-mail: harleen.k.sandhu@uth.tmc.edu

    Back to Top | Article Outline

    • Miscellaneous •

    NCT01604577

    Targeting Social Determinants to Improve Chronic Kidney Disease Care

    Ages eligible for study: 18 years to 80 years

    Sponsors and collaborators: Vanderbilt University

    Contact: Kerri Cavanaugh, MD

    Phone: 615-936-7306

    E-mail: kerri.cavanaugh@vanderbilt.edu

    Back to Top | Article Outline
    NCT01624064

    Renal Effects of an Angiotensin-Converting Enzyme Inhibitor in Adults with Chronic Kidney Disease of Uncertain Etiology (CKDu)

    Ages eligible for study: 18 years to 70 years

    Sponsors and collaborators: Ministry of Health, Sri Lanka; World Health Organization

    Contact: Selvarajah Mathu, MBBS, MD

    Phone: 94-77-7390628

    E-mail: mathuselvarajah@yahoo.com

    Contact: Navaratnasingam Janakan, MBBS, MSc, MD

    Phone: 94-77-7489813

    E-mail: navajanakan@yahoo.com

    Back to Top | Article Outline
    NCT01616927

    Study of Lanreotide to Treat Polycystic Kidney Disease (DIPAK1)

    Ages eligible for study: 18 years to 60 years

    Sponsors and collaborators: University Medical Center Groningen, Leiden University Medical Center, Erasmus Medical Center, Radboud University

    Contact: Esther Meijer, MD, PhD

    E-mail: esther.meijer@umcg.nl

    Contact: Ron Gansevoort, MD, PhD

    E-mail: r.t.gansevoort@umcg.nl

    Back to Top | Article Outline
    NCT01604395

    Long-Term Safety and Effectiveness of Growth Hormone with GHD (Growth Hormone Deficiency), TS (Turner Syndrome), CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature) in Children (LGS)

    Ages eligible for study: 2 years and older

    Sponsors and collaborators: LG Life Sciences

    Contact: YoungHwan Jang

    Phone: 82-2-6924-3158

    E-mail: younghj@lgls.com

    © 2012 Lippincott Williams & Wilkins, Inc.